Introduction - Diabetes has been identified as a risk factor for severe forms of COVID-19. The objective of our study was to analyze all COVID-19 hospitalizations among people with diabetes using data from the National Health Data System (SNDS) and to describe their main characteristics and regional variations. Methods - People with diabetes receiving pharmacological treatment residing in France (excluding Mayotte) were identified based on the dispensing of an antidiabetic medication on at least three different dates (two if at least one large package was dispensed) during the year 2019. Hospital stays with a confirmed diagnosis of COVID-19 were identified by a primary, related, or associated diagnosis coded as U07.10, U07.11, U07.12, U07.14, or U07.15. Stays of less than one day were excluded, except for stays during which a death occurred. Hospitalizations in intensive care units (ICUs) and continuous monitoring units (Ursic) were identified based on medical units 01A, 01B, 02A, 02B, 03A, 03B, 13A, 13B, 14A, 14B, and 18. Results - During the first half of 2020, 19,315 people receiving pharmacological treatment for diabetes were hospitalized for COVID-19 in France, representing approximately 20% of all individuals hospitalized for COVID-19 during that period. Among people with diabetes, 30.0% were admitted to the ICU and 24.2% died in the hospital. People with diabetes hospitalized for COVID-19 were predominantly men (60.3%), with an average age of 72.1 years (standard deviation = 12.8) and were receiving insulin therapy in 37.1% of cases. The overall hospitalization rate for COVID-19 among people receiving pharmacological treatment for diabetes was 0.56%, but increased with age, exceeding 1% among those over 85 years old. It also varied by region: Île-de-France (1.25%), French Guiana (1.09%), and Grand Est (1.00%). The hardest-hit departments were Haut-Rhin (1.86%) and Seine-Saint-Denis (1.62%). Conclusion - People with diabetes are paying a heavy price in the current health crisis: 30% of those hospitalized for COVID-19 were admitted to the ICU, and nearly a quarter died in the hospital. These findings underscore the importance of prevention for people with diabetes, particularly adherence to protective measures and vaccination. It is also essential to emphasize the importance of diabetes screening and clinical follow-up to prevent the onset of complications.